LP-118
- Generic Name
- LP-118
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Phase 1
Not yet recruiting
- Conditions
- Acute LeukemiaLymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 33
- Registration Number
- NCT06207123
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1
Recruiting
- Conditions
- Richter TransformationT-cell-prolymphocytic LeukemiaMyelodysplastic/Myeloproliferative NeoplasmSmall Lymphocytic LymphomaMyelodysplastic Neoplasm in Blast PhaseNon Hodgkin LymphomaMultiple MyelomaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyeodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 100
- Registration Number
- NCT04771572
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath